-
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Study. Clin Cancer Res. 2026 Mar 04. Yu EY, Narayan V, Esposito G, Szmulewitz R, Lu Y, Lilly MB, Calais J, Bratslavsky G, Menda Y, Vasanawala M, Pouliot F, Laidley D, Fleshner N, Saad F, Provost JC, Teslenko I, Rawat NK, Ulaner G. PMID: 41779000.
-
Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA. J Nucl Med. 2026 Feb 12. Nikitas J, Holzgreve A, Juarez J, Kimura K, Lira S, Alam H, Contreras M, Theus L, Nguyen AT, Ells Z, Zhu S, Grogan T, Elashoff DA, Unterrainer LM, Dahlbom M, Allen-Auerbach M, Czernin J, Calais J. PMID: 41679923.
-
PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program. J Nucl Med. 2026 Feb 12. Kimura K, Murthy V, Voter AF, Solnes LB, Moradi Tuchayi A, Yadav S, Theus L, Nguyen A, Ludwig V, Holzgreve A, Unterrainer LM, Grogan TR, Czernin J, Hope TA, Gafita A, Calais J. PMID: 41679922.
-
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study. J Nucl Med. 2026 Feb 02; 67(2):246-252. Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira S, Nabong RM, Gardner L, Gonzalez BD, Gafita A, Czernin J, Calais J. PMID: 41344853.
-
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy. J Natl Compr Canc Netw. 2026 Feb; 24(2):11-18. Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle LF, Nickols NG, Steinberg ML, Czernin J, Kishan AU, Calais J. PMID: 41698328.
-
Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy. J Nucl Med. 2026 Jan 02; 67(1):12-14. Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. PMID: 41233144; PMCID: PMC12766870.
-
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2026 Jan 02; 67(1):92-95. Djaileb L, Farolfi A, Rauscher I, Haghighatian M, Mercier A, Fendler WP, Hadaschik B, Herrmann K, Solnes LB, Rettig M, Weber M, Czernin J, Calais J, Benz MR, Eiber M, Gafita A. PMID: 41167722.
-
FAP Expression in Renal Tumors Assessed by [68Ga]Ga-FAPI-46 PET Imaging and FAP Immunohistochemistry: A Case Series of Six Patients from the Prospective Exploratory Trial NCT04147494. J Nucl Med. 2026 Jan 02; 67(1):49-52. Holzgreve A, Unterrainer LM, Flores K, Lam EC, Mona CE, Czernin J, Shuch BM, Sisk AE, Calais J. PMID: 41101974; PMCID: PMC12766859.
-
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. J Clin Oncol. 2025 Dec 20; 43(36):3812-3821. Kishan AU, Valle LF, Wilhalme H, Felix C, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom M, Lauria M, Meyer C, Cao M, Weidhaas JB, Telesca D, McGreevy K, Nickols NG, Karasik D, Parmisano S, Basehart TV, Brisbane W, Marks L, Rettig MB, Reiter RE, Boutros PC, Allen-Auerbach M, Czernin J, Steinberg ML, Calais J. PMID: 41223345; PMCID: PMC12711279.
-
Prognostic Value of AI-Assisted Lesion Tracking on End-of-Treatment PSMA PET in mCRPC Patients Treated with 177Lu-PSMA: A Retrospective, Single-Center Study. J Nucl Med. 2025 Nov 03; 66(11):1690-1694. Murthy V, Kimura K, Theus L, Nguyen A, Lokre O, Perk T, Thin P, Nguyen K, Ludwig V, Chen L, Gafita A, Czernin J, Calais J. PMID: 40998723.
-
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival. Cancer. 2025 Nov 01; 131(21):e70131. Gogebakan KC, Elsisi Z, Montano-Campos F, Owens L, Zhao Y, Gulati R, Ferdinandus J, Fendler WP, Calais J, Hope TA, Carlsson S, Fainberg J, Laudone V, Kunst N, Berlin A, Schipper M, Barbour A, Iravani A, Etzioni R. PMID: 41108673; PMCID: PMC12632154.
-
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. J Nucl Med. 2025 Oct 01; 66(10):1639-1645. Holzgreve A, Delker A, Ells Z, Brosch-Lenz J, Unterrainer LM, Nikitas J, Zhu S, Contreras MM, Alam H, Nabong RM, Lira S, Vasilyev A, Chen L, Grogan T, Elashoff D, Meyer CA, Dahlbom M, Czernin J, Calais J. PMID: 40876952; PMCID: PMC12487728.
-
From Nuclear Medicine Specialist to Cancer Center Director: Jeremie Calais Talks with Pierre Vera about Leading Through Change in Nuclear Medicine. J Nucl Med. 2025 Oct 01; 66(10):1503-1505. Vera P, Calais J. PMID: 40935612.
-
Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar 01; 124(3):647-650. Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter RE, Rettig MB, Steinberg ML, Sisk A, Brisbane W, Marks LS, Boutros PC, Lilleby WH, Kishan AU. PMID: 41105052.
-
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Front Oncol. 2025; 15:1583168. Beltran H, Calais J, Emmett L, Kuo PH, Logothetis CJ. PMID: 40909956; PMCID: PMC12405329.
-
PSMA/FDG discordance: 24-hour [177Lu]-PSMA-617 SPECT versus 60-minute [68Ga]-PSMA-11 PET. Eur J Nucl Med Mol Imaging. 2026 Mar; 53(4):2195-2196. Mercier A, De Leiris N, Calais J, Ludwig VB, Farolfi A, Gafita A, Djaileb L. PMID: 40702229.
-
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. 2025 Aug; 8(4):893-898. Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriseti S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. PMID: 40541485; PMCID: PMC12311854.
-
The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025 Jun 02; 66(6):833-838. Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. PMID: 40015925.
-
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy. Target Oncol. 2025 Jul; 20(4):597-613. Kuo PH, Calais J, Crosby M. PMID: 40418317; PMCID: PMC12307550.
-
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025 Nov; 88(5):484-495. Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP, PROMISE Registry Group. PMID: 40318933.
-
RECIP 1.0: A Roadmap for Clinical Implementation. J Nucl Med. 2025 May 01; 66(5):673-675. Gafita A, Djaileb L, Calais J, Eiber M, Fendler WP. PMID: 40147848.
-
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025 Aug; 52(10):3700-3708. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. PMID: 40137974.
-
Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study. Radiother Oncol. 2025 Jun; 207:110869. Hotta M, Nguyen K, Thin P, Armstrong WR, Sonni I, Farolfi A, Steinberg M, Czernin J, Nickols NG, Kishan AU, Calais J. PMID: 40122284.
-
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually). J Nucl Med. 2025 Mar 03; 66(3):333-336. Czernin J, Bodei L, Modlin I, Calais J. PMID: 39915128.
-
Future directions in the evaluation and management of newly diagnosed metastatic cancer. Crit Rev Oncol Hematol. 2025 Apr; 208:104631. Lehrer EJ, Khunsriraksakul C, Garrett S, Trifiletti DM, Sheehan JP, Guckenberger M, Louie AV, Siva S, Ost P, Goodman KA, Dawson LA, Tchelebi LT, Yang JT, Showalter TN, Park HS, Spratt DE, Kishan AU, Gupta GP, Shah C, Fanti S, Calais J, Wang M, Schmitz K, Liu D, Abraham JA, Dess RT, Buvat I, Solomon B, Zaorsky NG. PMID: 39864534.
-
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 03; 66(1):54-60. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. PMID: 39753363.
-
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025 Jan 03; 66(1):26-33. Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, Oprea-Lager DE, Trimnal L, Zan E, Herrmann K, Deroose CM. PMID: 39572227; PMCID: PMC11705787.
-
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 01 02; 8(1):e2452971. Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 39752157; PMCID: PMC11699533.
-
Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. J Nucl Med. 2024 Dec 03; 65(12):1923-1931. Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, Grogan T, Ahuja P, Barroso N, Zong Y, Soin P, Sisk A, Czernin J, Hsu W, Calais J, Reiter RE, Raman SS. PMID: 39477501.
-
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024 Dec 03; 65(12):1952-1958. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. PMID: 39477498; PMCID: PMC11619584.
-
Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice. J Nucl Med. 2024 Dec 03; 65(12):1851-1854. Jadvar H, Iravani A, Bodei L, Calais J. PMID: 39299786.
-
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. PMID: 39616467; PMCID: PMC11694557.
-
Molecular imaging of renal cell carcinomas: ready for prime time. Nat Rev Urol. 2025 06; 22(6):336-353. Wu Q, Shao H, Zhai W, Huang G, Liu J, Calais J, Wei W. PMID: 39543358.
-
Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur Urol. 86(1) (2024) 52-60]. Eur Urol. 2025 Jan; 87(1):97-99. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 39521695.
-
Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 01; 65(11):1789-1794. Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. PMID: 39362770; PMCID: PMC11927094.
-
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Nov 01; 65(11):1740-1744. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. PMID: 39327018.
-
Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2024 Nov 01; 65(11):1666-1671. Calais J, Morris MJ, Kendi AT, Kalebasty AR, Tutrone R, Anderson MJ, Sartor O. PMID: 39362764; PMCID: PMC11533911.
-
Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep. 2024 10 18; 14(1):24411. Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. PMID: 39420060; PMCID: PMC11487247.
-
Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024 Dec; 70:36-42. Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J, Reiter RE. PMID: 39483519; PMCID: PMC11525452.
-
Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024 Oct 01; 65(10):1571-1576. Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I. PMID: 39168522.
-
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Dec; 86(6):579-587. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. PMID: 39294048; PMCID: PMC11637967.
-
Characterization of a gonadal vein Capillary Hemangioma by [68Ga]FAPI-46 and [18 F]FDG PET and immunohistochemistry: a potential pitfall of FAPI PET signal. Eur J Nucl Med Mol Imaging. 2025 Jan; 52(2):785-786. Hotta M, Seyedroudbari A, Dry S, Girgis M, Calais J. PMID: 39227425.
-
Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Sep 03; 65(9):1387-1394. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. PMID: 39089811.
-
Standardized template for clinical reporting of PSMA PET/CT scans. Eur J Nucl Med Mol Imaging. 2024 Dec; 52(1):335-341. Esfahani SA, Morris MJ, Sartor O, Frydenberg M, Fanti S, Calais J, Vapiwala N. PMID: 39143250; PMCID: PMC11599343.
-
Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. J Nucl Med. 2024 Aug 01; 65(8):1264-1271. Ells Z, Grogan TR, Czernin J, Dahlbom M, Calais J. PMID: 38960712; PMCID: PMC11294071.
-
Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul; 8:e2400161. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU. PMID: 39013135; PMCID: PMC11770880.
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). J Nucl Med. 2024 Jul 01; 65(7):1076-1079. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. PMID: 38664019; PMCID: PMC11218723.
-
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Jun 03; 65(6):917-922. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. PMID: 38637143.
-
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug; 212(2):299-309. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. PMID: 38758680.
-
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024 Sep; 51(11):3373-3385. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. PMID: 38750372.
-
PSMA PET/CT Dual-Time-Point Imaging: Nice to Have or Need to Have? J Nucl Med. 2024 May 01; 65(5):818-819. Unterrainer LM, Ruchalski K, Allen-Auerbach MS, Calais J, Benz MR. PMID: 38176724.
-
[68Ga]Ga-FAPI-46 PET in a Borderline Ovarian Tumor. J Nucl Med. 2024 May 01; 65(5):820-821. Unterrainer LM, Memarzadeh S, Moatamed NA, Benz MR, Czernin J, Calais J. PMID: 38212069.
-
Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2(4). Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774467; PMCID: PMC11107999.
-
Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4). Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. PMID: 38774466; PMCID: PMC11108024.
-
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Jun; 85(6):517-520. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. PMID: 38494380; PMCID: PMC11386258.
-
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Jun; 85(6):511-516. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. PMID: 38490855.
-
Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024 03 01; 65(3):438-445. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. PMID: 38238041; PMCID: PMC12530667.
-
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease. J Nucl Med. 2024 Feb 15. Kishan AU, Siva S, Hofman MS, Nagarajah J, Kiess AP, Tran P, Calais J. PMID: 38360048.
-
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024 Jul; 86(1):52-60. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. PMID: 38290964; PMCID: PMC12882065.
-
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer. Annu Rev Med. 2024 01 29; 75:49-66. Unterrainer LM, Calais J, Bander NH. PMID: 38285513.
-
Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2024 01 02; 65(1):59-62. Maliha PG, Hotta M, Czernin J, Calais J. PMID: 37945382.
-
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024 01 02; 65(1):94-99. Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, Eiber M, Roberts MJ, Agrawal S, Franklin A, Xue A, Rasiah K, John N, Moon D, Frydenberg M, Yaxley J, Stricker P, Wong K, Coughlin G, Gianduzzo T, Kua B, Ho B, Nguyen A, Liu V, Lee J, Hsiao E, Sutherland T, Perry E, Fendler WP, Hope TA. PMID: 38050155.
-
ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals. Am J Clin Oncol. 2024 04 01; 47(4):169-176. Wallner PE, Yoo DC, Calais J, Escorcia FE, Mari Aparici C, Michalski J, Morris M, Morris ZS, Pryma D, Rabatic BM, Sharma N, Vapiwala N, Ghesani MV, Subramaniam RM, Small W, Schechter NR. PMID: 38131352.
-
Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30; 13(1):95. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. PMID: 37902861; PMCID: PMC10616012.
-
Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 11; 64(11):1772-1778. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. PMID: 37797974; PMCID: PMC10626377.
-
Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 02; 7(1):18. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. PMID: 37779132; PMCID: PMC10542625.
-
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023 11; 64(11):1712-1720. Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL. PMID: 37678928; PMCID: PMC10626373.
-
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 11; 64(11):1744-1747. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. PMID: 37591547; PMCID: PMC11927057.
-
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States. J Nucl Med. 2023 Sep; 64(9):1359-1360. Czernin J, Calais J. PMID: 37562803.
-
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 12; 84(6):588-596. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. PMID: 37482512.
-
68Ga-FAPI-46 PET/CT Tracer Uptake in CT-diagnosed Intra-Abdominal Fat Necrosis. Radiol Imaging Cancer. 2023 07; 5(4):e230026. Maliha PG, Allen-Auerbach M, Hotta M, Calais J. PMID: 37389447; PMCID: PMC10413291.
-
Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 07; 308(1):e222148. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. PMID: 37432081; PMCID: PMC10374938.
-
PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy. J Nucl Med. 2023 09; 64(9):1502-1503. Murthy V, Allen-Auerbach M, Lam R, Owen D, Czernin J, Calais J. PMID: 37321828.
-
Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023 Sep; 50:102461. Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, Marks LS. PMID: 37358989; PMCID: PMC10285561.
-
Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023; 2023:2480493. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. PMID: 37333052; PMCID: PMC10275689.
-
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423. Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST, Taplin ME, Sartor O, Morris MJ. PMID: 37290800.
-
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 06; 24(6):597-610. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. PMID: 37269841; PMCID: PMC10641914.
-
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023 07; 50(9):2830-2845. Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. PMID: 37246997; PMCID: PMC10317889.
-
Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [68Ga]Ga-FAPI-46 PET-Positive and [18F]FDG PET-Negative. J Nucl Med. 2023 11; 64(11):1839-1840. Maliha PG, Mendelsohn AH, Czernin J, Howard T, Calais J, Hotta M. PMID: 37230532.
-
A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023 08; 64(8):1259-1265. Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. PMID: 37230533; PMCID: PMC10394308.
-
Editorial Comment. J Urol. 2023 08; 210(2):299-311. Eifer M, Hope TA, Calais J, Hofman MS. PMID: 37203346; PMCID: PMC12721600.
-
FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells. Clin Nucl Med. 2023 Jul 01; 48(7):e353-e355. Hotta M, Mona CE, Crompton JG, Armstrong WR, Gafita A, Nelson SD, Eilber FC, Dawson DW, Calais J, Benz MR. PMID: 37146173.
-
Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. J Nucl Med. 2023 05; 64(5):678-681. Morris MJ, Calais J, Czernin J. PMID: 37055221.
-
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 07; 64(7):1024-1029. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PMID: 36997329; PMCID: PMC11937727.
-
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023 05; 83(5):405-412. Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. PMID: 36935345.
-
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 04; 6(2):224-227. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. PMID: 36870853.
-
LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 07; 132(1):65-74. Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan AU. PMID: 36797449.
-
Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 08 01; 116(5):1079-1084. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. PMID: 36863416.
-
The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. J Nucl Med. 2023 03; 64(3):343. Czernin J, Calais J. PMID: 36863780.
-
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev. 2023 Apr; 115:102524. Calais J, Eulau SM, Gardner L, Hauke RJ, Kendi AT, Shore ND, Zhao S. PMID: 36933329.
-
68Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 06; 64(6):902-909. Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PMID: 36759200; PMCID: PMC10241009.
-
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. PMID: 36725249.
-
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. J Nucl Med. 2023 06; 64(6):869-872. Gudenkauf LM, Chavez MN, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. PMID: 36635088; PMCID: PMC10241017.
-
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 04; 50(5):1466-1486. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schöder H, Wan S, Wester HJ, Hope TA, Herrmann K. PMID: 36604326; PMCID: PMC10027805.
-
Incidental Focal 68Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion. J Nucl Med. 2023 06; 64(6):992. Maliha PG, Jafarvard M, Czernin J, Calais J, Hotta M. PMID: 36581376.
-
Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting. Prostate. 2023 02; 83(3):207-226. Miyahira AK, Hawley JE, Adelaiye-Ogala R, Calais J, Nappi L, Parikh R, Seibert TM, Wasmuth EV, Wei XX, Pienta KJ, Soule HR. PMID: 36443902.
-
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 01; 12(1):65. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. PMID: 36182983; PMCID: PMC9526774.
-
Non-oncologic incidental uptake on FAPI PET/CT imaging. Br J Radiol. 2023 Feb; 96(1142):20220463. Hotta M, Rieger AC, Jafarvand MG, Menon N, Farolfi A, Benz MR, Calais J. PMID: 35776566; PMCID: PMC9975522.
-
More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. J Nucl Med. 2022 07; 63(7):969-970. Czernin J, Adams T, Calais J. PMID: 35772954.
-
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022 Oct; 49(12):4271-4281. Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. PMID: 35767071.
-
How Many Theranostics Centers Will We Need in the United States? J Nucl Med. 2022 06; 63(6):805-806. Czernin J, Calais J. PMID: 35649664.
-
Tumor Sink Effect: Myth or Reality? J Nucl Med. 2022 07; 63(7):1124. Gafita A, Calais J, Fendler WP, Eiber M. PMID: 35483966.
-
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. J Nucl Med. 2022 11; 63(11):1651-1658. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M. PMID: 35422442; PMCID: PMC9635677.
-
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-17. Gafita A, Marcus C, Kostos L, Schuster DM, Calais J, Hofman MS. PMID: 35609224.
-
PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply. JAMA Oncol. 2022 04 01; 8(4):1. Hope TA, Calais J. PMID: 35175289.
-
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022 10; 63(10):1484-1488. Hotta M, Gafita A, Czernin J, Calais J. PMID: 35273096.
-
Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane Antigen. J Urol. 2022 Apr; 207(4):769-778. Kuppermann D, Calais J, Marks LS. PMID: 35085002.
-
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 12 01; 4(12):e2138550. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. PMID: 34902034; PMCID: PMC8669522.
-
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiother Oncol. 2022 01; 166:1-7. Ma TM, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Loblaw DA, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU. PMID: 34774650.
-
Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2022 07; 63(7):1021-1026. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. PMID: 34740953; PMCID: PMC9258565.
-
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. J Nucl Med. 2021 Nov; 62(11):1489-1491. Calais J, Czernin J. PMID: 34725231; PMCID: PMC8612346.
-
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Nov 01; 7(11):1635-1642. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. PMID: 34529005; PMCID: PMC8446902.
-
Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. J Nucl Med. 2022 06; 63(6):847-854. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter RE, Calais J. PMID: 34649942; PMCID: PMC9157724.
-
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. J Nucl Med. 2022 Jan; 63(1):76-80. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohamad O, Pampaloni MH, Scott PJH, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert M. PMID: 34620731; PMCID: PMC8717195.
-
18F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma. J Nucl Med. 2022 05; 63(5):708-712. Crompton JG, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. PMID: 34593596; PMCID: PMC9051595.
-
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022 Jan; 63(1):59-68. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. PMID: 34593595; PMCID: PMC8717184.
-
High 68 Ga-FAPI-46 uptake in a pulmonary necrotizing granuloma in a patient with subcutaneous lipoma. Eur J Nucl Med Mol Imaging. 2022 02; 49(3):1088-1089. Hotta M, Benz MR, Allen-Auerbach MS, Crompton JG, Roth MD, Eilber FC, Calais J. PMID: 34546387.
-
Salvage therapy for prostate cancer after radical prostatectomy. Nat Rev Urol. 2021 11; 18(11):643-668. Zaorsky NG, Calais J, Fanti S, Tilki D, Dorff T, Spratt DE, Kishan AU. PMID: 34363040.
-
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. J Nucl Med. 2022 04; 63(4):567-572. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. PMID: 34326126; PMCID: PMC8973291.
-
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2022 Feb; 63(2):199-204. Benz MR, Armstrong WR, Ceci F, Polverari G, Donahue TR, Wainberg ZA, Quon A, Auerbach M, Girgis MD, Herrmann K, Czernin J, Calais J. PMID: 34272317.
-
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med. 2021 Oct; 62(10):1447-1456. Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Dahlbom M, He B, Esfandiari R, Ranganathan D, Herrmann K, Eiber M, Fendler WP, Delpassand E. PMID: 34272322; PMCID: PMC8724902.
-
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021 08; 22(8):1115-1125. Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, Sandhu S, Kratochwil C, Esfandiari R, Tauber R, Zeldin A, Rathke H, Armstrong WR, Robertson A, Thin P, D'Alessandria C, Rettig MB, Delpassand ES, Haberkorn U, Elashoff D, Herrmann K, Czernin J, Hofman MS, Fendler WP, Eiber M. PMID: 34246328.
-
177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine. J Nucl Med. 2021 Aug 01; 62(8):1025-1026. Czernin J, Calais J. PMID: 34330737.
-
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients. Eur J Nucl Med Mol Imaging. 2021 12; 48(13):4377-4385. Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, Sennung D, Roehrich M, Debus J, Sathekge M, Haberkorn U, Calais J, Serfling S, Buck AL. PMID: 34137945; PMCID: PMC8566651.
-
Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality? J Nucl Med. 2022 02; 63(2):226-232. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. PMID: 34049987; PMCID: PMC8805781.
-
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 Oct; 62(10):1440-1446. Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, Nguyen K, Lok V, Gosa L, Grogan T, Esfandiari R, Allen-Auerbach M, Quon A, Bahri S, Gupta P, Gardner L, Ranganathan D, Slavik R, Dahlbom M, Herrmann K, Delpassand E, Fendler WP, Czernin J. PMID: 34016732; PMCID: PMC8724893.
-
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021 May 07; 21(1):512. Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, Herrmann K, Czernin J, Kishan AU, Nickols NG, Elashoff D, Fendler WP. PMID: 33962579; PMCID: PMC8103642.
-
Reply to Alexa R. Meyer, Steven P. Rowe, and Nirmish Singla's Letter to the Editor re: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, et al. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. Eur Urol 2021;79:107-11. Integrating 99mTc-sestamibi and ONEX to Optimize Risk Stratification for Renal Masses. Eur Urol. 2021 07; 80(1):e22-e23. Shuch B, Raman S, Calais J. PMID: 33941405.
-
Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 05; 299(2):248-260. Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. PMID: 33787338.
-
Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. J Nucl Med. 2021 Nov; 62(11):1511-1516. Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I. PMID: 33674400; PMCID: PMC8612343.
-
Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. Eur Urol Oncol. 2021 06; 4(3):339-355. Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU. PMID: 33637464.
-
We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. Eur Urol Focus. 2021 03; 7(2):227-228. Fendler WP, Calais J. PMID: 33612416.
-
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 02; 5(1):100-103. Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. PMID: 33602654; PMCID: PMC10262977.
-
PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021 02 27; 397(10276):768-769. Hope TA, Calais J. PMID: 33581799.
-
Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. J Nucl Med. 2021 02; 62(2):146-148. Sartor O, Hope TA, Calais J, Fendler WP. PMID: 33468543.
-
Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer. Clin Nucl Med. 2021 Feb 01; 46(2):e86-e87. Hayrapetian A, Girgis MD, Yanagawa J, French SW, Schelbert HR, Auerbach MS, Czernin J, Calais J. PMID: 32701818.
-
The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. J Nucl Med. 2021 Sep 01; 62(9):1244-1251. Armstrong WR, Gafita A, Zhu S, Thin P, Nguyen K, Alano R, Lira S, Booker K, Gardner L, Grogan T, Elashoff D, Allen-Auerbach M, Dahlbom M, Czernin J, Calais J. PMID: 33509974; PMCID: PMC9364769.
-
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur Urol Focus. 2021 03; 7(2):238-240. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. PMID: 33386288; PMCID: PMC8057677.
-
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade? Point-An Important Diagnostic, Phenotypic, and Biomarker Role. AJR Am J Roentgenol. 2021 02; 216(2):305-306. Calais J, Mona CE. PMID: 32755205.
-
A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 09; 80(3):280-292. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. PMID: 33309278; PMCID: PMC10262981.
-
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. J Nucl Med. 2021 Jul 01; 62(7):989-995. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. PMID: 33277393; PMCID: PMC8882874.
-
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial. EJNMMI Res. 2020 Oct 15; 10(1):122. Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, Federman N. PMID: 33063147; PMCID: PMC7561652.
-
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2022 10; 5(5):544-552. Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J. PMID: 32958451.
-
The Impact of 18F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. Adv Radiat Oncol. 2020 Nov-Dec; 5(6):1364-1369. Parikh NR, Tsai S, Bennett C, Lewis M, Sadeghi A, Lorentz W, Cheung M, Garraway I, Aronson W, Kishan AU, Bahri S, Vahidi K, Calais J, Ishimitsu D, Rettig M, Nickols NG, Jafari L. PMID: 33305100; PMCID: PMC7718503.
-
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 11; 80(15):1273-1296. Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR. PMID: 32865839; PMCID: PMC8442561.
-
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. Eur J Nucl Med Mol Imaging. 2021 02; 48(2):501-508. Fendler WP, Calais J, Eiber M, Simko JP, Kurhanewicz J, Santos RD, Feng FY, Reiter RE, Rettig MB, Nickols NG, Kishan AU, PSMA PET Reader Group, Slavik R, Carroll PR, Lawhn-Heath C, Herrmann K, Czernin J, Hope TA. PMID: 32808077; PMCID: PMC7835157.
-
68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation. Eur J Nucl Med Mol Imaging. 2021 03; 48(3):924-926. Sonni I, Lee-Felker S, Memarzadeh S, Quinn MM, Mona CE, Lückerath K, Czernin J, Calais J. PMID: 32651662.
-
PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics. Clin Nucl Med. 2020 Jul; 45(7):e309-e310. Sonni I, Caron J, Kishan AU, Muthusamy VR, Calais J. PMID: 32404709.
-
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020 08; 78(2):148-154. Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, Calais J, Rauscher I, Rathke H, Tauber R, Delpassand ES, Weber WA, Herrmann K, Czernin J, Eiber M, Hofman MS. PMID: 32532512.
-
Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. Front Med (Lausanne). 2020; 7:218. Truffault B, Bourhis D, Chaput A, Calais J, Robin P, Le Pennec R, Lucia F, Leclère JC, Gujral DM, Vera P, Salaün PY, Schick U, Abgral R. PMID: 32582727; PMCID: PMC7287148.
-
Nuclear Medicine, Molecular Imaging, and Theranostics: The Future Is Bright. J Nucl Med Technol. 2020 Jun; 48(Suppl 1):82S-83S. Czernin J, Calais J. PMID: 32605963.
-
PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. Radiology. 2020 07; 296(1):44-55. Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, Davenport MS. PMID: 32396045.
-
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. J Nucl Med. 2020 12; 61(12):1793-1799. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, Wu IK, Lawhn-Heath C, Pampaloni MH, Reiter RE, Rettig MB, Gartmann J, Murthy V, Slavik R, Carroll PR, Herrmann K, Calais J, Hope TA. PMID: 32358094; PMCID: PMC9364898.
-
FAP: The Next Billion Dollar Nuclear Theranostics Target? J Nucl Med. 2020 02; 61(2):163-165. Calais J. PMID: 31924719.
-
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med. 2020 08; 61(8):1153-1160. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter RE, Czernin J, Calais J. PMID: 31924715; PMCID: PMC7413232.
-
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2020 08; 61(8):1171-1177. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. PMID: 31836685; PMCID: PMC7413240.
-
Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. J Nucl Med. 2020 07; 61(7):1037-1042. Farolfi A, Ilhan H, Gafita A, Calais J, Barbato F, Weber M, Afshar-Oromieh A, Spohn F, Wetter A, Rischpler C, Hadaschik B, Pianori D, Fanti S, Haberkorn U, Eiber M, Herrmann K, Fendler WP. PMID: 31806773; PMCID: PMC7383079.
-
Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Res. 2019 Dec 02; 9(1):103. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. PMID: 31792771; PMCID: PMC6889088.
-
Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. J Nucl Med. 2019 12; 60(12):1657-1658. Czernin J, Allen-Auerbach M, Calais J. PMID: 31792126.
-
Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020 03; 61(3):405-411. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. PMID: 31541035; PMCID: PMC7067527.
-
Reply by Authors. J Urol. 2019 12; 202(6):1181. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. PMID: 31524577.
-
The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med. 2019 09; 60(Suppl 2):3S-12S. Czernin J, Sonni I, Razmaria A, Calais J. PMID: 31481589.
-
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 09; 20(9):1286-1294. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. PMID: 31375469; PMCID: PMC7469487.
-
Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? J Nucl Med. 2020 02; 61(2):189-193. Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. PMID: 31324710; PMCID: PMC8801954.
-
Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. J Urol. 2019 08; 202(2):231-240. Tan N, Bavadian N, Calais J, Oyoyo U, Kim J, Turkbey IB, Mena E, Davenport MS. PMID: 30829130.
-
68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol. 2019 12; 202(6):1174-1181. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, Briganti A, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. PMID: 31233369.
-
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593; PMCID: PMC6567829.
-
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019 09; 60(9):1266-1269. Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. PMID: 30850506; PMCID: PMC6735279.
-
Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 01 21; 19(1):97. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30665383; PMCID: PMC6341574.
-
Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 Jan 07; 19(1):18. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. PMID: 30616601; PMCID: PMC6322287.
-
Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. J Nucl Med. 2019 01; 60(1):1-2. Razmaria A, Calais J, Czernin J. PMID: 30602593.
-
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2019 06; 60(6):786-793. Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. PMID: 30530831; PMCID: PMC6581235.
-
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2018 12; 45(13):2253-2255. Ceci F, Polverari G, Calais J, Castellucci P. PMID: 30232540.
-
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. PMID: 30374743; PMCID: PMC6206308.
-
Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. PMID: 29653978; PMCID: PMC6225538.
-
Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 09; 59(9):1392-1397. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. PMID: 29602819; PMCID: PMC6910618.
-
Reply: Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. J Nucl Med. 2018 05; 59(5):861. Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. PMID: 29496985.
-
The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 04; 59(4):557-567. Calais J, Cao M, Nickols NG. PMID: 29301928; PMCID: PMC6910632.
-
Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. PMID: 29242398; PMCID: PMC5868499.
-
Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2018 05; 59(5):789-794. Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F. PMID: 29242404.
-
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. PMID: 29123013; PMCID: PMC5807533.
-
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018 03; 59(3):469-478. Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP. PMID: 29123012.
-
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. J Nucl Med. 2017 09; 58(Suppl 2):67S-76S. Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL. PMID: 28864615.
-
Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. PMID: 28473600; PMCID: PMC5666645.
-
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 10; 58(10):1617-1623. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. PMID: 28408531.
US